世界各地抗凝门诊简介及其对中国内地抗凝管理的启示

[1] 韩国抗凝治疗管理模式简介 [J]. 齐鲁药事, 2008, (06) : 354 - 356

[2] 心血管疾病合理用药专家圆桌会纪要 [J]. 中国医院用药评价与分析, 2006, (01) : 1 - 5

[3] 中国心房颤动现状的流行病学研究 [J]. 中华内科杂志, 2004, (07) : 15 - 18

[4] Incidence and predictors of severe bleeding during warfarin treatment [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2008, 25 (02) : 151 - 159

[5] Cost-Justification of a Clinical Pharmacist-Managed Anticoagulation Clinic[J] . David R. Gray,Susan M. Garabedian-Ruffalo,Steven D. Chretien.Annals of Pharmacotherapy . 2007 (3)

[6] Reorganisation of an anticoagulation clinic using a telemedicine system: description of the model and preliminary results[J] . Sophie Testa,Adriano Alatri,Oriana Paoletti,Giampietro Morstabilini,Maria Anunzia Medagliani,Nadia Denti,Emanuela Martellenghi.Internal and Emergency Medicine . 2006 (1)

[7] Guidelines on oral anticoagulation （warfarin）: third edition – 2005 update[J] . T. P.Baglin,D. M.Keeling,H. G.Watson.British Journal of Haematology . 2005 (3)

[8] Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population [J]. PHARMACOGENETICS AND GENOMICS, 2005, 15 (10) : 687 - 691

[9] Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate‐intensity anticoagulation?[J] . J. H. S.You,F. W. H.Chan,R. S. M.Wong,G.Cheng.British Journal of Clinical Pharmacology . 2005 (5)

[10] Differences in warfarin dose requirements between A-sian and Caucasian patients. Weibert RT,Palinkas LA. Clinical Pharmacology and Therapeutics . 1991

[1] 韩国抗凝治疗管理模式简介 [J]. 齐鲁药事, 2008, (06) : 354 - 356

[2] 心血管疾病合理用药专家圆桌会纪要 [J]. 中国医院用药评价与分析, 2006, (01) : 1 - 5

[3] 中国心房颤动现状的流行病学研究 [J]. 中华内科杂志, 2004, (07) : 15 - 18

[4] Incidence and predictors of severe bleeding during warfarin treatment [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2008, 25 (02) : 151 - 159

[5] Cost-Justification of a Clinical Pharmacist-Managed Anticoagulation Clinic[J] . David R. Gray,Susan M. Garabedian-Ruffalo,Steven D. Chretien.Annals of Pharmacotherapy . 2007 (3)

[6] Reorganisation of an anticoagulation clinic using a telemedicine system: description of the model and preliminary results[J] . Sophie Testa,Adriano Alatri,Oriana Paoletti,Giampietro Morstabilini,Maria Anunzia Medagliani,Nadia Denti,Emanuela Martellenghi.Internal and Emergency Medicine . 2006 (1)

[7] Guidelines on oral anticoagulation （warfarin）: third edition – 2005 update[J] . T. P.Baglin,D. M.Keeling,H. G.Watson.British Journal of Haematology . 2005 (3)

[8] Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population [J]. PHARMACOGENETICS AND GENOMICS, 2005, 15 (10) : 687 - 691

[9] Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate‐intensity anticoagulation?[J] . J. H. S.You,F. W. H.Chan,R. S. M.Wong,G.Cheng.British Journal of Clinical Pharmacology . 2005 (5)

[10] Differences in warfarin dose requirements between A-sian and Caucasian patients. Weibert RT,Palinkas LA. Clinical Pharmacology and Therapeutics . 1991